Bioscience

InNexus antibody technology causes cancer cell death

March 23, 2010

By Flinn Foundation

[Source: Market Watch] – InNexus Biotechnology Inc., commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL(TM)) technology, today announces the Journal of Anti-Cancer Drugs is publishing the manuscript titled, “The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis” by Bingaman et al.

The manuscript showcases in detail how InNexus’ lead product, DXL625 (anti-CD20) induces apoptosis (cell death) in cancer cells, having a mechanism not previously seen with commercially available antibody drugs including Rituxan(R). Comparison experiments were also conducted with Rituxan(R) to confirm this unique cell killing ability.

For more information: InNexus Bio DXL(TM) Antibody Technology Causes Cancer Cell Death By Mechanisms Not Seen with Current Market-Leading Medications